BSGI/MBI: Effective for Detecting Breast Cancer In Dense and Non-Dense Breasts: RSNA 2011 | RSNA 2011
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
Conferences Past Conferences RSNA 2011 BSGI/MBI: Effective for Detecting Breast Cancer In Dense and Non-Dense Breasts: RSNA 2011

BSGI/MBI: Effective for Detecting Breast Cancer In Dense and Non-Dense Breasts: RSNA 2011

Medical Conferences News - RSNA 2011

Unlike mammography, BSGI, also known as MBI, is as effective in detecting breast cancer in women with dense and non-dense breasts, these findings will be presented at the RSNA 2011.

Unlike mammography, Breast-Specific Gamma Imaging (BSGI), also known as Molecular Breast Imaging (MBI), is as effective in detecting breast cancer in women with dense and non-dense breasts. These findings will be presented at the 2011 Radiological Society of North America ( RSNA 2011 ) annual meeting to be held in Chicago, Nov. 27 through Dec. 2, 2011.

"Dense breast tissue is extremely common, occurring in 50 percent of pre-menopausal and 40 percent of post-menopausal women, and is a strong risk factor for developing breast cancer," said Rachel Brem, M.D., first author of this study from The George Washington University Medical Center, Washington, D.C. "However, mammography is far less effective in women with dense breasts, missing 35 percent to 45 percent of breast cancers in these women." Mammography in women with dense breasts is limited and necessitates additional imaging modalities that are not impacted by breast density.

"As we increasingly appreciate the importance breast density has on risk for developing breast cancer and the limitations of mammography, it is crucial that we find technologies that allow for the detection of breast cancer, regardless of risk," said Dr. Brem. "It is exciting that BSGI does exactly that and can be used to detect breast cancer in all women, regardless of density."

Under new legislation, mammography clinics in Connecticut and Texas are now required to inform patients about their breast density. While other states may follow suit, doctors are already using advanced diagnostic imaging tools that are effective in the detection of cancer in both dense and non-dense breasts.

Researchers from The George Washington University Medical Center (Washington, D.C.) conducted a retrospective review of their BSGI database from January 2004 to August 2009. They evaluated 344 women with breast cancer, of whom breast density was available per mammography report. Researchers included Rachel F. Brem, M.D.; Caitrin M. Coffey, BS; Jocelyn A. Rapelyea, M.D.; Jessica Torrente, M.D.; Jennifer H. Lieberman, BA; Megan R. Kann, BA; Anita McSwain, M.D., MPH; and Christine Teal.

Results found there was no difference in the sensitivity of BSGI/MBI in detecting breast cancer in women with non-dense and dense breasts. The overall sensitivity of BSGI/MBI for breast cancer detection was 95.6 percent; 137 of 142 (96.5 percent) women with non-dense breasts, and 192 of 202 (95.1 percent) women with dense breasts had positive BSGI/MBI examinations.

"The ability to utilize physiologic imaging to improve breast cancer detection is very exciting in that it is equally effective in women with dense and non-dense breasts," said Dr. Brem. "The sensitivity of BSGI has been reported to be equal to MRI, but BSGI is performed with the patient comfortably seated. BSGI requires a fraction of the physician time for image interpretation, has a lower false positive rate, and can be performed in women who cannot undergo MRI, such as those with implantable devices and renal insufficiency. The integration of BSGI in clinical practice is a robust tool for the improved detection of the smallest cancers: those which are detected early, and are most curable," said Dr. Brem.

Source: Dilon Diagnostics